专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240067936A1 ONCOLYTIC VIRUS AND USES THEREOF 审中-公开
公开(公告)号：US20240067936A1
公开(公告)日：2024-02-29
申请号：US18278879
申请日：2022-02-25
申请人： SILLAJEN, INC.
发明人： Keunhee OH , Namhee LEE , Byung Jin JUNG , Jun Seung LEE , Kyeong Tae KANG
IPC分类号： C12N7/00 , A61K35/768 , A61P35/00 , C07K14/07 , C07K14/535 , C07K14/705 , C12N9/12 , C12N15/62
CPC分类号： C12N7/00 , A61K35/768 , A61P35/00 , C07K14/07 , C07K14/535 , C07K14/70596 , C12N9/1211 , C12N15/62
摘要： The present invention relates to an oncolytic virus and the use thereof, specifically, an oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such an oncolytic virus. The oncolytic virus of the present invention maintains its efficacy even when administered intravenously, and thus, it may also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to complement attack by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity when intravenous injection, and thus, it may reduce effective viral dosage to minimize the side effects of anti-cancer drugs.

2. 发明公开

US20240016865A1 ONCOLYTIC VIRUSES TARGETING STAT3 审中-公开
公开(公告)号：US20240016865A1
公开(公告)日：2024-01-18
申请号：US18452307
申请日：2023-08-18
申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH STSTEM OF HIGHER EDUCATION
发明人： Stephen Howard Thorne , Daniel J. Byrd
IPC分类号： A61K35/768 , C12N9/10 , C12N9/16 , A61P35/00 , A61K9/00 , C07K14/07 , C07K14/16 , C07K14/47 , C12N15/62
CPC分类号： A61K35/768 , C12N9/104 , C12Y301/03048 , C12N9/16 , A61P35/00 , A61K9/0019 , C07K14/07 , C07K14/16 , C07K14/4702 , C12N15/625 , C12N2710/24132 , C12N2710/24143 , C07K16/2827
摘要： This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.

3. 发明申请

US20220133825A1 ONCOLYTIC VIRUSES TARGETING STAT3 有权
公开(公告)号：US20220133825A1
公开(公告)日：2022-05-05
申请号：US17574763
申请日：2022-01-13
申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： Stephen Howard Thorne , Daniel J. Byrd
IPC分类号： A61K35/768 , C07K14/47 , A61K9/00 , C07K14/16 , C12N9/10 , C07K14/07 , C12N9/16 , A61P35/00 , C12N15/62 , C07K16/28
摘要： This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.

4. 发明授权

US09150616B2 Immunoregulatory peptides and methods of use 有权
公开(公告)号：US09150616B2
公开(公告)日：2015-10-06
申请号：US13753106
申请日：2013-01-29
申请人： 13 Therapeutics, Inc.
发明人： Sharon L. McCoy , Steven H. Hefeneider
IPC分类号： A61K38/10 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/07 , C07K14/005 , A61K38/00
CPC分类号： A61K39/285 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/07 , C07K14/47 , C07K2319/10 , C12N2710/24122
摘要： Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.

5. 发明授权

US09133440B2 Generation of new pancreatic beta cells 有权
标题翻译：新胰腺β细胞的产生
公开(公告)号：US09133440B2
公开(公告)日：2015-09-15
申请号：US13662253
申请日：2012-10-26
申请人： Claresa Levetan
发明人： Claresa Levetan
IPC分类号： C12N5/071 , C07K14/07 , C07K14/435 , A61K35/39
CPC分类号： C12N5/0676 , A61K35/39 , C07K14/07 , C07K14/435 , C12N2501/998
摘要： The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.
摘要翻译：本发明涉及用于治疗新的和现有的1型和2型糖尿病，糖尿病前期，成人潜伏性自身免疫性糖尿病，胰岛素缺乏症，β细胞缺乏症，胰岛素抵抗和葡萄糖代谢障碍的新型疗法。特别地，本发明鉴定人Reg1a，Reg1b，Reg3a和Reg4内的常见肽，作为通过人胰腺胰岛组织表面上的人Reg受体作用的β细胞产生的信号肽。本发明鉴定了Reg受体的特异性结合区，其中开发了肽模拟物和刺激性抗体用于产生新的β细胞，其可以直接施用于具有所述病症包括1型糖尿病，2型糖尿病，糖尿病前期和其他病症的患者的β细胞缺乏症，并提供了保护用于1型糖尿病和成人潜伏性自身免疫性糖尿病的新型β细胞的具体方法。本发明还提供了使用本文所述的发明的β细胞的离体产生和递送。

6. 发明授权

US08637315B2 Process, vectors and engineered cell lines for enhanced large-scale transfection 有权
标题翻译：过程，载体和工程细胞系，用于增强大规模转染
公开(公告)号：US08637315B2
公开(公告)日：2014-01-28
申请号：US12989898
申请日：2009-03-09
申请人： Yves Durocher , Martin Loignon
发明人： Yves Durocher , Martin Loignon
IPC分类号： C12N15/87 , C07K14/07
CPC分类号： C12N15/85 , C07K14/005 , C07K2319/71 , C12N2710/16222 , C12N2710/16622 , C12N2800/108 , C12N2800/40
摘要： Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).
摘要翻译：描述了用于哺乳动物细胞，特别是中国仓鼠卵巢（CHO）细胞中大规模转染和蛋白质生产的载体和工程细胞系，其中转染效率通过使用单一载体系统实现，使用功能性oriP序列所有质粒，使用密码子优化的爱泼斯坦 - 巴尔病毒核抗原-1（EBNA1）构建了截短的爱泼斯坦 - 巴尔病毒核抗原-1（EBNA1c）蛋白和单纯疱疹病毒蛋白VP16之间的融合蛋白，使用40kDa完全脱乙酰化的聚（亚乙基亚胺）作为转染试剂，使用共表达成纤维细胞生长因子（FGF）和/或使用蛋白激酶B来加强丙戊酸的异源基因表达增强（ VPA）。

7. 发明申请

US20060222658A1 Vaccinia virus nucleic acids, polypeptides and immunogenic compositions 审中-公开
标题翻译：牛痘病毒核酸，多肽和免疫原性组合物
公开(公告)号：US20060222658A1
公开(公告)日：2006-10-05
申请号：US11291305
申请日：2005-11-30
申请人： David Roth , Huaping He
发明人： David Roth , Huaping He
IPC分类号： A61K39/12 , C07H21/04 , C12N15/86 , C12P21/06 , C07K14/07
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/5154 , A61K2039/5156 , A61K2039/53 , C12N2710/24122 , C12N2710/24134
摘要： The present invention provides transcriptionally active vaccinia virus polynucleotides, recombinant vaccinia virus polypeptides, and immunogenic vaccinia virus antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines.
摘要翻译：本发明提供转录活性痘苗病毒多核苷酸，重组痘苗病毒多肽和免疫原性痘苗病毒抗原。还提供可用作重组，亚单位和DNA疫苗的免疫原性组合物。

8. 发明授权

US06838553B1 Peptide repeat immunogens 失效
标题翻译：肽重复免疫原
公开(公告)号：US06838553B1
公开(公告)日：2005-01-04
申请号：US09412558
申请日：1999-10-05
申请人： Jaulang Hwang , Chia-Tse Hsu , Chun-Jen Ting
发明人： Jaulang Hwang , Chia-Tse Hsu , Chun-Jen Ting
IPC分类号： A61K39/00 , C07K7/23 , C07K14/07 , C07K14/21 , C12N15/16 , C12N15/31 , C12N15/39 , C07H21/04 , C07H21/02
CPC分类号： C07K14/005 , A61K39/00 , C07K7/23 , C07K14/21 , C07K2319/00 , C12N2710/24122
摘要： The invention relates to a polypeptide including (1) a receptor binding domain of a Pseudomonas exotoxin A, and (2) at least two copies of a peptide sequence.
摘要翻译：本发明涉及包括（1）假单胞菌外毒素A的受体结合结构域的多肽，和（2）肽序列的至少两个拷贝。

9. 发明授权

US6140472A Use of chimeric vaccinia virus complement control proteins to inhibit complement 失效
标题翻译：使用嵌合痘苗病毒补体对照蛋白抑制补体
公开(公告)号：US6140472A
公开(公告)日：2000-10-31
申请号：US201075
申请日：1998-11-30
申请人： Ariella M. Rosengard , Joseph M. Ahearn, Jr. , Alfred P. Sanfilippo , William M. Baldwin, III
发明人： Ariella M. Rosengard , Joseph M. Ahearn, Jr. , Alfred P. Sanfilippo , William M. Baldwin, III
IPC分类号： A61K35/14 , A61K38/00 , C07K14/07 , C07K14/705 , C12N15/39 , C07K16/46
CPC分类号： C07K14/005 , C07K14/70596 , A01K2217/05 , A61K38/00 , C07K2319/00 , C12N2710/24122
摘要： Disclosed are chimeric proteins that are useful for inhibiting complement. The chimeric protein termed VCPFc is a fusion protein in which (i) an immunoglobulin Fc region is fused to (ii) a polypeptide that comprises a portion of a vaccinia virus complement control protein which binds complement components C4b and C3b, but not iC3b rosettes. This protein can be used in xenograft transplantation methods (e.g., by treating the donor mammal or organ) and in methods for treating complement-mediated disorders (e.g., inflammation) generally. In a second chimeric protein, a transmembrane anchoring domain is fused to a polypeptide that comprises a portion of a vaccinia virus complement control protein which binds complement components C4b and C3b, but not iC3b rosettes. The transmembrane anchoring domain can be, for example, short consensus regions 3 through 15 of human complement receptor 2 protein. Expression of the transmembrane-anchored fusion protein in a transgenic animal provides a well-suited organ donor for xenograft transplantation.
摘要翻译：公开了可用于抑制补体的嵌合蛋白。称为VCPFc的嵌合蛋白是融合蛋白，其中（i）免疫球蛋白Fc区融合到（ii）包含部分痘苗病毒补体对照蛋白的多肽，其结合补体成分C4b和C3b，但不结合iC3b花环。该蛋白质可以用于异种移植物移植方法（例如通过治疗供体哺乳动物或器官）和通常用于治疗补体介导的病症（例如炎症）的方法。在第二嵌合蛋白中，跨膜锚定结构域融合到包含部分痘苗病毒补体对照蛋白的多肽，所述痘苗病毒补体对照蛋白结合补体成分C4b和C3b，但不结合iC3b玫瑰花结。跨膜锚定结构域可以是例如人补体受体2蛋白的短共有区域3至15。跨膜锚定的融合蛋白在转基因动物中的表达提供了用于异种移植物移植的非常适合的器官供体。

10. 发明授权

US5942235A Recombinant poxvirus compositions and methods of inducing immune responses 失效
标题翻译：重组痘病毒组合物和诱导免疫应答的方法
公开(公告)号：US5942235A
公开(公告)日：1999-08-24
申请号：US458356
申请日：1995-06-02
申请人： Enzo Paoletti
发明人： Enzo Paoletti
IPC分类号： C12N15/09 , A61K35/76 , A61K38/00 , A61K38/16 , A61K38/17 , A61K38/21 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/17 , A61K39/205 , A61K39/275 , A61K39/285 , A61K48/00 , A61P35/00 , A61P37/04 , C07H21/04 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/165 , C07K14/175 , C07K14/18 , C07K14/33 , C07K14/47 , C07K14/52 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/55 , C07K14/57 , C07K14/705 , C07K14/82 , C12N7/00 , C12N15/00 , C12N15/19 , C12N15/86 , C12N15/863 , C12P21/04
CPC分类号： C12N15/86 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/17 , A61K39/205 , A61K39/275 , A61K39/285 , C07K14/005 , C07K14/33 , C07K14/4746 , C07K14/525 , C07K14/535 , C07K14/5406 , C07K14/5434 , C07K14/55 , C07K14/57 , C07K14/705 , C07K14/70532 , C07K14/82 , C12N15/00 , C12N7/00 , A61K2039/5254 , A61K2039/5256 , A61K39/00 , C07K2319/00 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12022 , C12N2760/16122 , C12N2760/16134 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20022 , C12N2760/20122 , C12N2760/20134 , C12N2770/20022 , C12N2770/24022 , C12N2770/24122
摘要： Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN.gamma.; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.
摘要翻译：包含编码细胞因子和/或肿瘤相关抗原的DNA的减毒重组病毒以及采用病毒的方法和组合物被公开和要求保护。重组病毒可以是NYVAC或ALVAC重组病毒。 DNA可编码以下至少一种：人肿瘤坏死因子; 核磷蛋白p53，野生型或突变体; 人黑素瘤相关抗原; IL-2; IFNγ; IL-4; GMCSF; IL-12; B7; erb-B-2和癌胚抗原。重组病毒及其基因产物可用于癌症治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式